stockrowMeiraGTx Holdings PLC
MGTX Healthcare Biotechnology
MeiraGTx Holdings PLC’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 144.6% from fiscal 2024.
- Revenue
- +8,608.6%
- EPS
- +466.7%
- Free cash flow
- +13.1%
- Total debt
- +28.6%
Quarter to June 2026, against a year earlier
Follow MGTX
Alert me
MeiraGTx Holdings PLC (MGTX) EV/Sales
As of 6 November 2026, MeiraGTx Holdings PLC (MGTX) trades at a EV/Sales of 2.0×. Over the past ten years it has ranged from 0.0× (December 2019) to 67.0× (December 2023); the current reading is higher than 19% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 7.7× | (35.45%) |
| FY2024 | 11.9× | (55.01%) |
| FY2023 | 26.4× | 58.03% |
| FY2022 | 16.7× | (32.41%) |
| FY2021 | 24.7× | 0.74% |
| FY2020 | 24.5× | (28.92%) |
| FY2019 | 34.5× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.0× | (64.95%) |
| Mar 2026 | 8.6× | 11.71% |
| Dec 2025 | 7.7× | (68.33%) |
| Sep 2025 | 24.2× | 60.53% |
| 26 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LTGO Latigo Biotherapeutics Inc compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| MGTX MeiraGTx Holdings PLC | 2.0× |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.3× |
| SNDX Syndax Pharmaceuticals, Inc. compare | 3.6× |
| ALMS Alumis Inc. compare | 36.0× |
| AKTS Aktis Oncology, Inc. compare | 36.8× |
| PRME Prime Medicine, Inc. compare | 177× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)